Syros Reports First Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Syros Pharmaceuticals (SYRS) Tops Q1 EPS by 23c, Revenues Beat
May 6, 2021 7:51 AM EDTSyros Pharmaceuticals (NASDAQ: SYRS) reported Q1 EPS of ($0.23), $0.23 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $4.83 million versus the consensus estimate of $2.67 million.
First Quarter 2021 Financial Results
Revenues were $4.8 million for the first quarter of 2021, consisting of $4.0 million in revenue recognized under Syros collaboration with Global Blood Therapeutics, Inc. (GBT) and $0.8 million recognized under its collaboration with Incyte Corporation (Incyte). Syros recognized $2.4 million in revenue in the first quarter of 2020, including $2.2 million under its collaboration with GBT and $0.2 million under its collaboration with Incyte.Research and... More